Omeza
FDA-cleared regenerative wound care
About
Omeza is a commercial-stage advanced wound care company developing FDA-cleared regenerative products derived from marine sources. The company’s platform focuses on treating chronic wounds with innovative marine biomaterial technology, improving healing outcomes. Founded prior to 2026, Omeza operates in the U.S. market and generates revenue through product sales to healthcare providers and institutions. Their $8.5 million Series A financing round, co-led by Astanor and BluKap Ventures, is aimed at scaling their wound care platform and market presence.
Products
-
Advanced regenerative wound care product
— FDA-cleared marine-based wound care treatment enhancing healing for chronic wounds.
Customer sectors: healthcare providers, hospitals, specialty clinics
Market research & competitive positioning
Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Omeza — available to members.
Related Companies
Other startups in Biotech & Therapeutics
